Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Analysts at HC Wainwright boosted their Q2 2025 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a report issued on Tuesday, May 13th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will post earnings of ($1.08) per share for the quarter, up from their previous forecast of ($1.12). HC Wainwright has a "Buy" rating and a $53.00 price target on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals' FY2025 earnings at ($4.48) EPS, Q2 2026 earnings at ($1.34) EPS, FY2026 earnings at ($5.38) EPS, FY2027 earnings at ($5.70) EPS, FY2028 earnings at ($5.11) EPS and FY2029 earnings at ($3.61) EPS.
Other equities analysts have also issued reports about the company. Evercore ISI initiated coverage on Xenon Pharmaceuticals in a report on Wednesday. They set an "outperform" rating and a $55.00 target price for the company. The Goldman Sachs Group lowered their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a report on Thursday, April 17th. Wells Fargo & Company reduced their price objective on Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating for the company in a research report on Tuesday. Royal Bank of Canada reduced their price objective on Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating for the company in a research report on Tuesday. Finally, Needham & Company LLC reduced their price objective on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $54.82.
Read Our Latest Analysis on Xenon Pharmaceuticals
Xenon Pharmaceuticals Stock Up 2.4%
Shares of NASDAQ:XENE traded up $0.72 during trading on Thursday, hitting $30.29. 966,331 shares of the company traded hands, compared to its average volume of 511,566. The stock has a market capitalization of $2.32 billion, a price-to-earnings ratio of -10.74 and a beta of 1.21. The business's fifty day moving average is $34.10 and its 200-day moving average is $37.95. Xenon Pharmaceuticals has a one year low of $26.74 and a one year high of $46.00.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.07. The firm had revenue of $7.50 million during the quarter, compared to the consensus estimate of $1.64 million. During the same period in the prior year, the firm earned ($0.62) earnings per share.
Institutional Trading of Xenon Pharmaceuticals
Several large investors have recently added to or reduced their stakes in XENE. Caitong International Asset Management Co. Ltd acquired a new stake in Xenon Pharmaceuticals during the 1st quarter valued at $30,000. GF Fund Management CO. LTD. acquired a new stake in Xenon Pharmaceuticals during the 4th quarter valued at $63,000. Quarry LP acquired a new stake in Xenon Pharmaceuticals during the 4th quarter valued at $78,000. Blue Trust Inc. raised its stake in Xenon Pharmaceuticals by 140.3% during the 4th quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock valued at $95,000 after purchasing an additional 1,414 shares during the period. Finally, Avior Wealth Management LLC acquired a new stake in Xenon Pharmaceuticals during the 4th quarter valued at $101,000. 95.45% of the stock is owned by institutional investors and hedge funds.
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Articles
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
